PDF iconMORL 2018 Kidney Testing Requisition Form (Effective August 27, 2018)

The Clinical Diagnostics Service of the Molecular Otolaryngology and Renal Research Laboratories is a CLIA-approved, Joint Commission-accredited diagnostic laboratory.

Plasma Complement Factor I Level 
Atypical Hemolytic Uremic Syndrome 

Complement Factor I (FI; MW: 88 kDa) is an important regulator of complement activity triggered through the classical and alternative pathways. FI limits complement activation by cleaving surface-bound and fluid-phase C3b and C4b, preventing the assembly of the C3 and C5 convertases. Patients with FI mutations may have reduced plasma FI levels and/or function, and are at-risk to develop atypical hemolytic uremic syndrome or C3 glomerulopathy.

Indications for screening 
Testing is appropriate for patients with aHUS.

MORL screening methodology 
Radial immunodiffusion (RID)

Turnaround time 
Turnaround time is ~2 weeks.

Sample Required 
1 ml frozen EDTA plasma (see testing requisition for specimen handling).

Cost & CPT Codes
See the MORL testing menu